Structure Elucidation and Activity of Kolossin A, the d-ß-Pentadecapeptide Product of a Giant Nonribosomal Peptide Synthetase**

Helge B. Bode,* Alexander O. Brachmann, Kirtikumar B. Jadhav, Lydia Seyfarth, Christina Dauth, Sebastian W. Fuchs, Marcel Kaiser, Nick R. Waterfield, Holger Sack, Stefan H. Heinemann, and Hans-Dieter Arndt*

Dedicated to Professor Peter B. Dervan on the occasion of his 70th birthday

Abstract: The largest continuous bacterial nonribosomal peptide synthetase discovered so far is described. It consists of 15 consecutive modules arising from an uninterrupted, fully functional gene in the entomopathogenic bacterium Photorhabdus luminescens. The identification of its cryptic biosynthesis product was achieved by using a combination of genome analysis, promoter exchange, isotopic labeling experiments, and total synthesis of a focused collection of peptide candidates. Although it belongs to the growing class of d-ß-peptide natural products, the encoded metabolite kolossin A was found to be largely devoid of antibiotic activity and is likely involved in interspecies communication. A stereoisomer of this peculiar natural product displayed high activity against Trypanosoma brucei rhodesiense, a recalcitrant parasite that causes the deadly disease African sleeping sickness.

Advanced sequencing methods and bioinformatics-based analysis have enabled the investigation of underexplored or even unknown compounds in natural products research.[1–4] The determination of their constitution has greatly profited from improvements in MS-based methods.[5–9] Furthermore, advances in genomic data acquisition and correlation has enabled prediction of the product stereochemistry of polyketides and nonribosomal peptide synthetases (NRPSs) with increasing fidelity.[10–15] However, in order to make putative products of cryptic biosynthesis accessible for further research, material from fermentation must be isolated on a preparative scale. With only analytical amounts of material accessible, chemical synthesis becomes increasingly important with respect to determining the identity and stereochemistry of the products of cryptic gene clusters, as well as for assigning their bioactivity and function.

Particularly challenging in this regard are very large gene clusters that cannot easily be cloned or expressed in heterologous hosts, as well as producer organisms with a complex life style, such as symbionts or species-selective pathogens. Herein, we describe the computational prediction of the cryptic biosynthesis product kolossin A (1) from Photorhabdus luminescens, the induced expression of its single 1.8 MDa NRPS Kol, and the stringent confirmation of the formylated d-ß-pentadecapeptide product structure (1) through labelling experiments and chemical synthesis, which also enabled bioactivity profiling.

In the genome of the entomopathogenic model bacterium Photorhabdus luminescens TTO1, several biosynthesis gene clusters have been characterized that are involved in the biosynthesis of diverse natural products.[12,13] Among them we identified the kol gene (plu2670, 49.1 kbp), which encodes the (to our knowledge) largest single NRPS of bacterial origin (Kol) with a predicted molecular weight of 1.81 MDa, a size
comparable to that of the bacterial ribosome. Detailed analysis indicated 15 NRPS modules with 45 domains (Figure 1) and Kol was thus expected to produce a pentadcapeptide. However, we were unable to detect such peptides under a variety of fermentation conditions, including cultivation of *P. luminescens* in the larvae of the greater waxmoth *Galleria mellonella* to imitate the natural life cycle of *Photorhabdus* (data not shown). Similarly, transcription analysis by RNAseq did not show significant activation of the *kol* gene, either in the exponential or stationary growth phases or in the presence of insect hemolymph (Figure S1 in the Supporting Information). Fortunately, artificial activation of this silent gene cluster could be achieved by applying a promoter exchange approach as described earlier to the *kol* gene, thus resulting in the detection of three novel biosynthesis products by HPLC–MS monitoring (Figure 2).

Unfortunately, the amount of material produced did not allow any detailed chemical analysis or structure determination. However, molecular formulae, as well as amino acid sequences, were delineated from MS experiments (Figure 1, Tables S3 and S4, and Figure S2). These data suggested the hydrophobic compound 1 to be the full-length kolossin A, with kolossin B (2) and kolossin C (3) as C-terminally truncated fragments. The configurations of the stereogenic centers were predicted based on the presence of dual condensation/epimerization (C/E) domains in Kol, which indicate fully alternating D-/L-configuration with the exception of two consecutive D-configurations at Val7 and Thr8 (Table S5). This places kolossin A among rare linear D-/L-peptide natural products such as gramicidin A, feglymycin, or the polytheonamides, all of which feature a propensity for β-helical structures and often show potent bioactivity. Interestingly, similar hydrophobic D-/L-depsipeptides, the xenoamicins, have been recently identified in *Xenorhabdus*, but with no linear derivatives.

To test the activity of the C/E domains in the Kol NRPS and thus the highly relevant configuration of the biosynthesis product, labeling experiments with fully deuterated alanine, valine, leucine, tyrosine, and threonine were performed in an ΔilvE mutant of *P. luminescens*. The loss of one deuterium atom for tyrosine and threonine (Figures S2 and S4) strongly suggest that at least the C/E domains following the Tyr- and Thr-incorporating modules 5, 8, and 12 were functional, and thus that both Thr residues should feature the D-configuration. The ΔilvE mutant is defective in the amino-transferase reaction for Leu and Ile and therefore was ideal for analyzing the epimerization of these amino acids. Indeed, incorporation of one L- and one D-leucine was detected for the truncated products 2 and 3, thus further supporting the proposed configuration of these amino acids.

The configuration at the β-substituted Thr residues was not directly accessible by isotopic labeling. In order to confirm the likely structure and provide material for bioactivity tests, access to synthetic kolossin A was necessary. Furthermore, to unequivocally validate the compound identity by LC–MS and to complement biological testing, chemical synthesis of stereoisomers was pursued. Accordingly, by employing permutations of D-allo-Thr, D-Thr, and L-
Threonine).

Angew. Chem. Int. Ed.

Scheme 1. (a) Structural formula of kolossin A (1). (b) Sequences of the investigated natural products 1–3 and isomers 4–11. Positions of variation (residue 8 and 12) and the backbone stereochemistry change between d (gray) and l (white) are highlighted, as well as the irregular continuation between residues 7 and 8 (aThr denotes allo-Threonine).

Figure 3. a) Structural formula of kolossin A (1). b) Sequences of the investigated natural products 1–3 and isomers 4–11. Positions of variation (residue 8 and 12) and the backbone stereochemistry change between d (gray) and l (white) are highlighted, as well as the irregular continuation between residues 7 and 8 (aThr denotes allo-Threonine).

All stereoisomers were independently synthesized by using Fmoc-based solid phase peptide synthesis (SPPS) \(^{22}\) on 2-chlorotrityl chloride resin. Peptides were sequentially assembled from C terminus to N terminus using an automated peptide synthesizer (Scheme 1). Considerable efforts based on precedence with difficult lipophilic \(\alpha\)-l-peptides \(^{24,25}\) led to an optimized synthetic method featuring a coupling cycle consisting of accelerated Fmoc deprotections, HBTU couplings in DMF as the solvent, and systemic capping (Scheme 1). Initial loading of resin 13 was 0.4 mmol/g. Conventional N-terminal formylation of fully deprotected \(\alpha\)-l-peptides in solution or by using standard reagents \(^{26}\) on resin-bound peptide led to impure products, apparently owing to lack of chemoselectivity and difficult removal of side products. Fortunately, formylation of the resin-bound, side-chain-protected peptide through treatment with saccharin formate (12) \(^{27}\) in THF was successful and selective for the terminal amino group. The crude peptides were released from the solid support and deprotected under carefully optimized conditions that left the N-terminal formyl group intact to give the corresponding kolossin A analogues 1 and 4–11 in more than 90% crude yields. The low solubility and the aggregation associated with these peptides were overcome by dissolving crude peptides in HFIP immediately prior to RP-HPLC purification (C4 column, MeOH/H2O, pH 3.5). On average, 20–23 mg of the kolossin A analogues were obtained from 100 mg of resin in high purity with excellent overall yields ranging from 31–34%. All compounds were fully characterized and distinguished by NMR spectroscopy and by their chromatographic properties despite their being diastereoisomeric in one amino acid side chain only. By using a combination of HPLC–MS and fragmentation analysis, the chemical structure and configuration of the scarce (\(\mu\)) natural product was clearly identified \(^{26}\).

Upon biological screening, neither kolossin A nor its analogues showed cytotoxicity against rat myoblast L6 cells or antibacterial activity against Gram-positive (Staphylococcus aureus, S. epidermis, Enterococcus faecalis, E. faecium) or Gram-negative (Escherichia coli wt, Klebsiella pneumonia, Proteus mirabilis, Pseudomonas aeruginosa) bacteria. To test pore-forming properties in membranes, as often associated with \(\alpha\)-l-peptides \(^{18–20}\), all of the candidates were investigated in a black lipid bilayer test system. None of the compounds was found to induce measurable conductivity (<1 \(\mu\)S) at a bath concentration of 1 mM (100 mM KCl, pH 8.0).
TRIS/HCl), whereas gramicidin A (gA) as a control induced conductivities up to 100 μS at 0.5 nm (Figure S6). Hence, the general pore-forming properties of the kolossins are 10^(-6)–10^(-7) fold less pronounced than for gA and likely absent at biological concentrations. Further tests of compounds 1 and 4-11 were carried out with the eukaryotic parasites Trypanosoma brucei rhodesiense, T. cruci, Leishmania donovani, and Plasmodium falciparum.[21,28] Notable activity (IC_{50} = 2.7 μM) was observed for compound 8 against T. brucei rhodesiense, the causative agent of African sleeping sickness, and for compound 11 against T. brucei r. (IC_{50} = 8.9 μM) and P. falciparum (IC_{50} = 16.1 μM), the causative agent of malaria (Table S6). All other isomers and the natural product itself were inactive.

In summary, bioinformatic prediction of a NRPS-derived peptide, stimulated overexpression, MS analysis and labelling experiments were combined to unequivocally prove the chemical structure and configuration of the giant silent peptide, stimulated overexpression, MS analysis and labelling conditions in the laboratory, our data suggest that the compound. In line with the observation that kolossin production of kolossin might require a specific signaling factor, potentially one connected to the insect host or a specific stage of its life cycle. The non-natural isomer 8 was found to be specifically active against T. brucei rhodesiense, a consistently fatal infection if untreated and a serious health issue in sub-Saharan Africa. Further studies will concentrate on pursuing this promising activity, as well as potentially linking it to the elusive endogenous function of kolossin in its producing bacterium P. luminescens.

Keywords: biological activity · biosynthesis · peptides · natural products · total synthesis


Received: March 27, 2015
Published online: ■■■■■ ■■■■■

These are not the final page numbers!
Sleeping giant: A 1.8 MDa nonribosomal peptide synthetase (NRPS) was identified in the entomopathogenic bacterium *Photorhabdus luminescens* and its production was activated. Its 15-mer d-/l-peptide product kolossin A was structurally characterized by combining genomic analysis of the silent gene cluster, molecular biology, LC–MS, and total synthesis. A stereoisomer of kolossin A was found to be active against the pathogen that causes African sleeping sickness.